F.D.OVCHARENKO INSITUTE OF BIOCOLLOIDAL CHEMISTRY

1
GOLD-BEARING PROBIOTIC DRUG OKARIN-AU
Workshop From Science to Business 11-12
October, 2006 Kyiv
Valeriya VEMBER Telephone [phone] vember_
imv_ua_at_mail.ru
F.D.OVCHARENKO INSITUTE OF BIOCOLLOIDAL CHEMISTRY
NATIONAL ACADEMY OF SCIENCES OF UKRAINE Kyiv
2
Proprietary information statement

• The technology material presented in this talk is
  available for licensing and joint product
  development.
• None of the slides contain any confidential or
  proprietary information.

1
3
The shape of gold-bearing probiotic preparation
"Okarin-Au"
2
4
3
5
4
6
Main problems as to probiotic drugs development
and application

• limited antagonistic activity of the
  strains-producers to the numerous pathogenic
  agents
• insufficient growth speed of biomass producing
  strains
• high cost of probiotic preparation as a result of
  using the expensive growth substances for
  strains-producers growing
• non-observance of the microecological adequacy
  principle while treatment of different
  dysbacteriosis types have been provided

5
7
6
8
ADVISABILITY of PROBIOTIC DRUG ENRICHMENT by
COLLOIDAL Au and Ag
9
Changes of biological activity of bacterial
association Okarin after incubation with GOLD
(10-6 mkg/ml) and SILVER (10-7 mkg/ml)
Metals Form Investigated indexes Investigated indexes Investigated indexes Investigated indexes Investigated indexes Investigated indexes Investigated indexes
Metals Form Growth intensity ATP-ase activity H -extrusion Perme-ability of the cell wall Level of lipid peroxi-dation Activity of antioxidant enzymes Activity of antioxidant enzymes
Metals Form Growth intensity ATP-ase activity H -extrusion Perme-ability of the cell wall Level of lipid peroxi-dation Catalase SOD
Au Colloidal ? ? ? ? ? 0 ?
Au Ion 0 0 0 ? 0
Ag Colloidal 0 ? 0 0 ?
Ag Ion ? ? ? ? ?
8
10
Resistance of Okarin andOkarin-Au to the
antibiotics
9
11

Antagonistic activity of bacterial association
Okarin and gold-bearing Okarin-Au
Microorganisms (test object) Size of lysis zone after 24 hours, mm Size of lysis zone after 24 hours, mm Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m) Quantity of test-culture (pieces) (? m)
Microorganisms (test object) Size of lysis zone after 24 hours, mm Size of lysis zone after 24 hours, mm Control Control after 12 hours after 12 hours after 24 hours after 24 hours after 72 hours after 72 hours
Microorganisms (test object) Okarin Okarin-Au Okarin Okarin- Au Okarin Okarin- Au Okarin Okarin- Au Okarin Okarin- Au
Shigella flexneri 1? 20 159 9 128 14 84 7 12 2
Sh. flexneri 1? 20 132 12 111 8 58 7 14 5
Sh. flexneri 2? 20 20 107 16 107 ? 16 92 4 96 ? 7 59 6 64 ? 8 27 8 9 ? 1
Sh. flexneri VI 20 20 183 5 183 ? 5 131 11 101 ? 10 81 10 47 ? 4 18 3 7 ? 3
Sh. sonnei 20 20 120 7 120 ? 7 92 3 89 ? 6 76 11 51 ? 6 25 4 18 ? 1
Salmonella enteritidis 20 20 100 14 100 ? 14 86 7 78 ? 3 51 2 47 ? 7 29 8 14 ? 3
S. thyphimurium 15 20 127 16 127 ? 16 120 7 85 ? 5 78 12 68 ? 2 25 7 16 ? 5
Staphylococcus aureus 15 20 116 6 116 ? 6 109 8 73 ? 4 59 11 60 ? 10 24 10 24 ? 5
Pseudomonas aeruginosa 15 20 110 2 110 ?2 104 9 81?11 79 3 64 ? 9 36 8 31 ? 2
Ps. vulgaris Not find 122 7 105 2 85 7 34 9
- behaviors, which show the
improvement of initial preparation Okarin
by colloidal gold.
10
12
Innovative Aspect and Main Advantages

• Wide range of antagonistic activity to pathogenic
  microorganisms causing dysbacteriosis and
  especially dangerous infection diseases including
  anthrax, rabbit-fever, salmonellosis, brucellosis
  etc. (according to results of clinical trials)
• Selective bactericidal activity to pathogenic
  microflora and simultaneous stimulation of
  normoflora. This feature is intensified owing to
  the presence of colloidal gold particles
• Low cost of the treatment course in a comparison
  with other probiotic drugs which are available on
  the market today
• Ability to increase the lysis of atypical
  pathological cells treatment application
  opportunity for oncological patients due to high
  resistance of probiotic's microbial cultures to
  antibiotics and chematherapeutic agents
• Non-specific immune-resistance stimulation
  ability of the whole organism
• Suitable producing shape and application
  simplicity.

11
13
Clinical trials results ofbacteriological
preparation "Okarin-Au"
Pathogenous species Staphylococcus aureus,
Enterobacter aerogenes, Klebsiella
pneumoniae, Candida albicans
12
14
Competitive Matrix of Probiotic
Probiotics Name Probiotics Characteristic Okarin-Au (IBCC-UkrInkom, Ukraine) Colibac-terinum (Biofarma, Ukraine) Hylak Forte (Ratiopharm, Germany) Linex (LekPharma, Slovakia) Bifiform (Ferrosan, Denmark)
Preparation Composition E. coli (3 strains) Enterococcus faecalis (dried alive cultures, enriched by colloidal Gold) 1113. Capsules. E. coli (strain M-17) (dried alive cultures) 11010 CFU/dose. Ampoules. Metabolites of E. coli, Streptococcus faecalis, Lactobacillus acidophilus and L. helveticus growth factors (aqueous solution) 2114. Bottles. Lactobacillus acidophilus, Bifidobacterium infantis, Enterococcus faecium (dried alive cultures) 1,2107 CFU/dose (each of strains). Capsules. Bifidobacterium longum and Enterococcus faecium (dried alive cultures) 1107 CFU/dose (each of strains). Capsules.
Antagonistic activity (AA) Shigella flexneri, Sh. sonnei, Salmonella enteritidis, S. thyphimurium, Staphylococ-cus aureus, Pseudomonas aeruginosa, Ps. vulgaris, Enterobacter aerogenes, Klebsiela pneumonia, Candida albicans Mixed infection of GIT and Salmonellosis. Prohibited to use in the case of Escherichiosis !!! Mixed infection of GIT and Salmonellosis Wide range of AA (accordance to preparation Instruction) Wide range of AA (accordance to preparation Instruction
Dosage regimen (per 24 hours) 2-3 capsules 6-12 doses 120-180 drops 6 capsules 2-4 capsules
Cost of treatment for 10 days 10 7 11 15 12,5
Complications and peculiarities of application ? 1) Require preliminary preparation 2) Prohibited to use at the same time with Antibiotics 1) Require preliminary measuring 2) Prohibited to use at the same time with Milk and Dairy Produce ? ?
13
15
O p p o r t u n i t i e s

• We seek for potential partners interested in new
  type of combined (and effective!) probiotic
  preparation and partners, who can help us in
  putting them on the market
• We are ready for collaboration with the purpose
  of creation of different synbiotic drugs which
  include wide range of colloidal metals and have
  different therapeutic effects

14
16
Contact Information

• Prof. Zoya ULBERG
• Telephone [phone]
• e-mail zulberg_at_bioco.kiev.ua

F.D.OVCHARENKO INSITUTE OF BIOCOLLOIDAL CHEMISTRY
NATIONAL ACADEMY OF SCIENCES OF UKRAINE Kyiv
15